ORGANON & CO. (OGN)
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
📈 **POSITIVE** • Medium confidence analysis (79%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business